Emergent BioSolutions Inc. (0IGA.L) LSE

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Joseph C. Papa Jr.	Chief Executive Officer, President & Director	2.49M	1956
Paul Williams	Senior Vice President of Products Business	765,052	1967
Simon C. Lowry	Chief Medical Officer & Head of Research and Development	845,170	1973
Coleen Glessner	Executive Vice President of Quality, Ethics & Compliance	1.04M	1971
Richard S. Lindahl	Executive VP & CFO	1.1M	1964
William Hartzel	Senior Vice President of Manufacturing & Bioservices	1.39M	1978
Jessica Perl	Senior Vice President, Corporate Secretary & General Counsel	0	1981
Michelle Pepin	Senior Vice President & Chief Human Resource Officer	0	N/A
Stephanie Duatschek	Chief Global Strategy & Franchise Development Officer	0	N/A
Frank Vargo	VP & Treasurer	0	N/A

Name

Title

Pay

Year Born

Joseph C. Papa Jr.

Chief Executive Officer, President & Director

2.49M

1956

Paul Williams

Senior Vice President of Products Business

765,052

1967

Simon C. Lowry

Chief Medical Officer & Head of Research and Development

845,170

1973

Coleen Glessner

Executive Vice President of Quality, Ethics & Compliance

1.04M

1971

Richard S. Lindahl

Executive VP & CFO

1.1M

1964

William Hartzel

Senior Vice President of Manufacturing & Bioservices

1.39M

1978

Jessica Perl

Senior Vice President, Corporate Secretary & General Counsel

1981

Michelle Pepin

Senior Vice President & Chief Human Resource Officer

N/A

Stephanie Duatschek

Chief Global Strategy & Franchise Development Officer

N/A

Frank Vargo

VP & Treasurer

N/A

Description

Emergent BioSolutions Inc. is a life sciences enterprise dedicated to developing and delivering solutions for preparing for and responding to diverse public health threats (PHTs) in the United States. Its mission involves countering unforeseen, intentional, and naturally arising health crises affecting populations. The company's product portfolio addresses a wide spectrum of PHTs, encompassing chemical, biological, radiological, nuclear, and explosive agents (CBRNE), emergent infectious diseases, travel-related health concerns, and immediate emergency medical needs. Among its key commercialized offerings are: Vaccines: BioThrax (for anthrax), ACAM2000 (for smallpox), Vivotif (an oral immunization against typhoid fever), and Vaxchora (a single-dose oral vaccine for cholera). Treatments & Antidotes: Botulism Antitoxin Heptavalent (combats botulism), vaccinia immune globulin intravenous (manages adverse reactions to smallpox vaccination), raxibacumab and Anthrasil (both for treating and preventing inhalational anthrax), and NARCAN (a nasal spray for immediate intervention in known or suspected opioid overdoses). Other Emergency Preparedness: Reactive skin decontamination lotion kits, and Trobigard, an investigational auto-injector product combining both drug and device components. Furthermore, Emergent BioSolutions boasts an active development pipeline, featuring candidates such as AP003 (a multidose Naloxone nasal spray), AP007 (a sustained-release Nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus-like particle vaccine), COVID-HIG (a treatment for SARS-CoV2), EGRD-001 (a diazepam auto-injector), SIAN (an antidote for acute cyanide poisoning), and UniFlu (a universal influenza vaccine). Beyond its proprietary products, the company also provides comprehensive contract development and manufacturing (CDMO) services. These services include drug substance and product manufacturing, packaging solutions, alongside specialized expertise in technology transfer, process optimization, and analytical development. Established in 1998, Emergent BioSolutions maintains its corporate headquarters in Gaithersburg, Maryland.